[ALXN] Alexion Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 28.04 B

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 127.19 Change: 1.34 (1.06%)
Ext. hours: Change: 0 (0%)

chart ALXN

Refresh chart

Strongest Trends Summary For ALXN

ALXN is in the long-term up 287% above S&P in 27 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding224.02 M EPS3.07 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 17.14% Sales Growth - Q/Q0.14% P/E37.13
P/E To EPS Growth P/S12.36 P/BV7.97 Price/Cash Per Share14.56
Price/Free Cash Flow55.69 ROA13.34% ROE16.74% ROI15.36%
Current Ratio4.92 Quick Ratio4.61 Long Term Debt/Equity0.05 Debt Ratio0.17
Gross Margin90.72% Operating Margin33.65% Net Profit Margin25.97% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities5.07 M Cash From Investing Activities-48.42 M Cash From Operating Activities23.03 M Gross Profit584.2 M
Net Profit170.22 M Operating Profit181.08 M Total Assets13.17 B Total Current Assets2.53 B
Total Current Liabilities769.17 M Total Debt3.5 B Total Liabilities4.61 B Total Revenue636.21 M
Technical Data
High 52 week141.3 Low 52 week93.94 Last close130.9 Last change-0.38%
RSI41.11 Average true range3.76 Beta1.14 Volume2.37 M
Simple moving average 20 days-1.22% Simple moving average 50 days-2.32% Simple moving average 200 days5.77%
Performance Data
Performance Week-0.6% Performance Month3.96% Performance Quart1.14% Performance Half10.45%
Performance Year9.39% Performance Year-to-date34.45% Volatility daily1.92% Volatility weekly4.28%
Volatility monthly8.78% Volatility yearly30.41% Relative Volume244.27% Average Volume1.33 M
New High New Low


2020-06-05 11:32:03 | Alexion ALXN Up 17.3% Since Last Earnings Report: Can It Continue?

2020-06-04 06:30:00 | Alexion to Present at the 41st Annual Global Goldman Sachs Healthcare Conference

2020-06-02 10:53:25 | AstraZeneca Ranked Most Inventive, Roche Most Innovative

2020-06-01 17:50:09 | Alexion Pharmaceuticals ALXN Stock Sinks As Market Gains: What You Should Know

2020-05-29 19:38:00 | Betting on Boeing to Fly Out of the Storm Clouds

2020-05-29 09:38:01 | Alexion ALXN Catches Eye: Stock Jumps 7.8%

2020-05-28 16:13:51 | Why This Event Could Clear The Deck For An Alexion Takeover: Analyst

2020-05-28 14:16:00 | Nasdaq Today: Why Alexion and Workday Stock Are Soaring

2020-05-28 09:49:32 | Dow Jones Today, Stocks Flatten As U.S., China Enter Cold War; Facebook Falls On White House Threat

2020-05-28 09:27:00 | Alexion Stock Jumps on Signal That Fight Over Patent May End Soon

2020-05-28 06:03:54 | Is Alexion Pharmaceuticals, Inc.'s NASDAQ:ALXN CEO Paid Enough Relative To Peers?

2020-05-27 13:05:57 | Hedge Funds Have Never Been This Bullish On Alexion Pharmaceuticals, Inc. ALXN

2020-05-15 16:48:00 | Macy’s and Portola See Investor Activists Buy Up Stakes

2020-05-14 13:47:00 | Alexion Stock Shows Rising Strength On Strong Earnings, Expansion Deals

2020-05-14 09:31:00 | Alexion Announces Upcoming Data Presentations at the Virtual 25th Congress of the European Hematology Association

2020-05-12 17:07:43 | Hedge Fund Tells Alexion Management to Sell Company

2020-05-12 12:34:39 | Activist investor Elliott pushes Alexion Pharma to sell itself

2020-05-12 08:55:33 | Elliott again pushes Alexion Pharma to explore a sale

2020-05-08 18:35:53 | 8 Stocks Ken Fisher Continues to Buy

2020-05-08 16:24:08 | Are Biotech ETFs in Trouble as Coronavirus Dims Guidance?

2020-05-07 13:24:00 | Teva’s CEO on Why the Generic Drugmaker Is Confident Despite Covid-19

2020-05-07 11:50:03 | Is Alexion Pharmaceuticals ALXN Stock Undervalued Right Now?

2020-05-06 16:49:12 | Edited Transcript of ALXN earnings conference call or presentation 6-May-20 12:00pm GMT

2020-05-06 16:22:06 | Alexion Skids On Trimmed 2020 Outlook Despite First-Quarter Beat

2020-05-06 13:31:35 | Alexion Pharmaceuticals Inc ALXN Q1 2020 Earnings Call Transcript

2020-05-06 11:26:03 | Alexion ALXN Beats on Q1 Earnings & Sales, Lowers Guidance

2020-05-06 11:19:00 | Alexion Stock Drops Despite Solid Earnings Because the Company Cut Guidance

2020-05-06 08:48:12 | Add Value to Your Portfolio With 5 High Earnings Yield Picks

2020-05-06 08:05:12 | Alexion Pharmaceuticals ALXN Tops Q1 Earnings and Revenue Estimates

2020-05-06 06:30:00 | Alexion Reports First Quarter 2020 Results

2020-05-05 16:30:00 | Alexion to Present at the Virtual Bank of America Securities 2020 Healthcare Conference

2020-05-05 16:02:00 | Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion

2020-05-05 15:10:00 | ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Portola Pharmaceuticals, Inc.

2020-05-05 12:42:00 | Why Portola Pharmaceuticals Is Skyrocketing Today

2020-05-05 11:13:00 | Alexion Will Buy Portola Pharmaceuticals for $1.4B

2020-05-05 10:42:00 | Alexion to Buy Portola for $18 a Share, or $1.41 Billion

2020-05-05 09:50:01 | Biotech Giant Alexion Swipes Blood Disease-Focused Portola In Buyout

2020-05-05 09:36:00 | Portola's stock more than doubles on heavy volume after Alexion buyout deal

2020-05-05 08:40:12 | Should You Buy Alexion ALXN Ahead of Earnings?

2020-05-05 08:13:00 | Alexion to Acquire Portola in $1.4 Billion Deal; Alexion's Attempts to Expand Beyond C5 Continue

2020-05-05 07:49:42 | Alexion to buy Portola Pharmaceuticals in $1.41 billion deal

2020-05-05 07:14:56 | Alexion to buy Portola Pharmaceuticals in $1.41 bln deal

2020-05-05 07:00:00 | Alexion to Acquire Portola

2020-05-04 15:12:59 | Trump expresses confidence for coronavirus vaccine ‘by the end of the year’

2020-05-04 12:10:04 | Why Alexion ALXN is Poised to Beat Earnings Estimates Again

2020-05-04 11:07:59 | Were Hedge Funds Right About Alexion Pharmaceuticals ALXN?

2020-05-04 09:15:01 | Zacks.com featured highlights include: LAUR, IMKTA, ALXN and CSIQ

2020-05-02 07:31:00 | Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals

2020-05-01 08:30:00 | Alexion Receives CHMP Positive Opinion for ULTOMIRIS® ravulizumab in Atypical Hemolytic Uremic Syndrome aHUS

2020-04-30 17:50:09 | Alexion Pharmaceuticals ALXN Stock Moves -0.9%: What You Should Know